Multiple entities in this group are defined by recurrent genetic alterations, such as MYB::NFIB and MYBL1::NFIB in adenoid cystic carcinoma [7, 8], MAML2 fusions in mucoepidermoid carcinoma [9], NR4A3 upregulation by enhancer hijacking in acinic cell carcinoma [10], or ETV6::NTRK3 in secretory carcinoma [11, 12]. This evidence concerns the gene NFIB and adenoid cystic carcinoma.